Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Uab Bioremedium is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 1 distinct examiner and are located within 1 distinct art unit. This indicates a high degree of concentration in the company's current prosecution activity, with all pending matters being reviewed by the same individual in the same specialized group.
The busiest examiner for the company is BENAVIDES, JENNIFER ANN, who is responsible for 2 busiest examiner pending actions. Because the total number of pending office actions is 2, this examiner is handling the entirety of the company's current workload in the Biotechnology & Pharmaceuticals sector. The presence of 1 distinct art unit further emphasizes the localized nature of the company's current patent office interactions. This singular focus on 1 distinct examiner and 1 distinct art unit means that the company's immediate prosecution success in this technology area depends on the outcomes of the 2 pending office actions under this specific examiner's review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENAVIDES, JENNIFER ANN | 2 | 50.8% | +47.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18390310 | Hydrogel Preparations for Acute and Chronic Wound Healing | BENAVIDES, JENNIFER ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18644676 | Hydrogel Preparations for Acute and Chronic Wound Healing | BENAVIDES, JENNIFER ANN | — |
| 18390310 | Hydrogel Preparations for Acute and Chronic Wound Healing | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18644676 | Hydrogel Preparations for Acute and Chronic Wound Healing | BENAVIDES, JENNIFER ANN | 1654 | §102§103§112DP | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18390310 | Hydrogel Preparations for Acute and Chronic Wound Healing | BENAVIDES, JENNIFER ANN | 1654 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUab Bioremedium has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Ann Benavides has the most, with 2 of Uab Bioremedium's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
